In a recent prospective study in 421 patients, the fluoroscopy time (FT) was measured. With QFR® the FT was only 47% of that of FFR and 30% of iFR. QFR® had the lowest dose-area product. Therefore, wider QFR® application in clinical practice could eliminate any additional exposure to ionizing radiation and increase the prevalence of physiology-guided coronary artery revascularization.
Read the article here
Learn more on the benefits of QFR®
